The PI3K/PTEN/AKT pathway is activated by the epigenetic suppression of PTEN and/or mutations in or amplification of individual components of the pathway in approximately 40–50% of patients with HCC [4–6]. This evidence concerns the gene PTEN and hepatocellular carcinoma.